RT Journal Article SR Electronic T1 Regional quantification of cardiac metabolism with hyperpolarized [1 - 13 C]-pyruvate MRI evaluated in an oral glucose challenge JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.10.16.23297052 DO 10.1101/2023.10.16.23297052 A1 Larson, Peder E. Z. A1 Tang, Shuyu A1 Liu, Xiaoxi A1 Sinha, Avantika A1 Dwork, Nicholas A1 Sivalokanathan, Sanjay A1 Liu, Jing A1 Bok, Robert A1 Ordovas, Karen G. A1 Slater, James A1 Gordon, Jeremy W. A1 Abraham, M. Roselle YR 2023 UL http://medrxiv.org/content/early/2023/10/19/2023.10.16.23297052.abstract AB Background The heart has metabolic flexibility, which is influenced by fed/fasting states, and pathologies such as myocardial ischemia and hypertrophic cardiomyopathy (HCM). Hyperpolarized (HP) 13C-pyruvate MRI is a promising new tool for non-invasive quantification of myocardial glycolytic and Krebs cycle flux. However, human studies of HP 13C-MRI have yet to demonstrate regional quantification of metabolism, which is important in regional ischemia and HCM patients with asymmetric septal/apical hypertrophy.Methods We developed and applied methods for whole-heart imaging of 13C-pyruvate, 13C-lactate and 13C-bicarbonate, following intravenous administration of [1-13C]-pyruvate. The image acquisition used an autonomous scanning method including bolus tracking, real-time magnetic field calibrations and metabolite-specific imaging. For quantification of metabolism, we evaluated 13C metabolite images, ratio metrics, and pharmacokinetic modeling to provide measurements of myocardial lactate dehydrogenase (LDH) and pyruvate dehydrogenase (PDH) mediated metabolic conversion in 5 healthy volunteers (fasting & 30 min following oral glucose load).Results We demonstrate whole heart coverage for dynamic measurement of pyruvate-to-lactate conversion via LDH and pyruvate-to-bicarbonate conversion via PDH at a resolution of 6×6×21 mm3 (13C-pyruvate) and 12×12×21 mm3 (13C-lactate, 13C-bicarbonate). 13C-pyruvate and 13C-lactate were detected simultaneously in the RV blood pool, immediately after intravenous injection, reflecting LDH activity in blood. In healthy volunteers, myocardial 13C-pyruvate-SNR, 13C-lactate-SNR, 13C-bicarbonate-SNR, 13C-lactate/pyruvate ratio, 13C-pyruvate-to-lactate conversion rate, kPL, and 13C-pyruvate-to-bicarbonate conversion rate, kPB, all had statistically significant increases following oral glucose challenge. kPB, reflecting PDH activity and pyruvate entering the Krebs Cycle, had the highest correlation with blood glucose levels and was statistically significant.Conclusions We demonstrate first-in-human regional quantifications of cardiac metabolism by HP 13C-pyruvate MRI that aims to reflect LDH and PDH activity.Competing Interest StatementPEZL and MRA received a research grant from Myokardia (now Bristol Myers Squibb). PEZL and JWG received a research grant from GE Healthcare. ST is an employee of HeartVista.Clinical TrialIND# 145169Funding StatementThis work was supported by funding from a UCSF Resource Allocation Program Team Science award, Myokardia Inc. Myoseeds program and NIH grants R33HL161816, P41EB013598, and U24CA253377. ND received post-doctoral training funding from the American Heart Association (grant number 20POST35200152).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants were recruited with UCSF Institutional Review Board approval (IRB #: 19-27889, PIs: Dr. Maria Roselle Abraham and Dr. Peder Larson) and gave informed consent prior to participation in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets analyzed during the current study are available from the corresponding author on reasonable request. Much of the data are in included in this published article and its supplementary information files.